MYND Life Sciences Inc. (MYNDF) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
MYND Life Sciences Inc. (MYNDF) trades at $0.0081. MYND Life Sciences Inc. is a neuro-pharmaceutical drug development company focused on creating medicines for depressive disorders. Sector: Healthcare.
Price as of Aug 20, 2026 · Last analyzed: Mar 18, 2026Analyst Coverage for MYNDF: MYNDF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates MYNDF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
MYNDF: 1/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →MYND Life Sciences Inc. (MYNDF) Healthcare & Pipeline Overview
MYND Life Sciences Inc. is a biotechnology company specializing in the development of neuro-pharmaceutical drugs targeting depressive disorders. Operating in the healthcare sector, the company focuses on research and clinical trials involving psilocin and psilocybin analogs within Canada and the United States, positioning itself in the evolving field of neuro-anti-inflammatory treatments.
What Is the Investment Thesis for MYNDF?
MYND Life Sciences Inc. presents a speculative investment opportunity within the burgeoning field of psychedelic-based therapeutics. The company's focus on psilocin and psilocybin analogs for depressive disorders positions it within a high-growth area of the biotechnology sector. A key value driver is the successful completion of clinical trials and subsequent regulatory approvals in Canada and the United States. Upcoming catalysts include the progression of drug candidates through clinical trial phases and potential partnerships with larger pharmaceutical companies. However, potential risks include regulatory hurdles, competition from other companies in the psychedelic medicine space, and the inherent uncertainty associated with drug development. The company's current P/E ratio of -2.18 reflects its pre-revenue status and reliance on future clinical and commercial success.
Based on FMP financials and quantitative analysis
MYNDF Key Highlights
MYND Life Sciences Inc. operates in the biotechnology industry, focusing on neuro-pharmaceutical drug development.
- The company specializes in medicines based on neuro-anti-inflammatory substances for depressive disorders.
- MYND Life Sciences Inc. conducts science and clinical trials in Canada and the United States.
- The company focuses on the analysis of psilocin and psilocybin extracts and analogs.
- MYND Life Sciences Inc. has a P/E ratio of -2.18, reflecting its current earnings status.
Who Are MYNDF's Competitors?
MYNDF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
| ADGI Adagio Therapeutics, Inc. | $4.64 | +0.87% | $506M | 71 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are MYNDF's Key Strengths?
Focus on innovative neuro-pharmaceutical drugs.
- Expertise in psilocin and psilocybin analogs.
- Established research and clinical trial infrastructure.
- Strategic partnerships with key stakeholders.
What Are MYNDF's Weaknesses?
Limited financial resources.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited commercialization experience.
What Could Drive MYNDF Stock Higher?
Progression of drug candidates through clinical trial phases.
- Potential partnerships with larger pharmaceutical companies.
- Regulatory approvals from health authorities in Canada and the United States.
- Expansion of research and development efforts.
- Securing additional funding through grants or investments.
What Are the Key Risks for MYNDF?
Financial-distress signal — its Altman Z-Score of -36.44 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Regulatory hurdles and changing regulations.
- Competition from established pharmaceutical companies.
- Uncertainty surrounding clinical trial outcomes.
- Limited financial resources.
- Dependence on successful clinical trial outcomes.
What Are the Growth Opportunities for MYNDF?
- Expansion of Clinical Trials: MYND Life Sciences has the opportunity to expand its clinical trials to include a broader range of depressive disorders and patient populations. The global market for depression treatment is estimated to reach $15.78 billion by 2030. Successful trials could lead to regulatory approvals and subsequent market entry, driving revenue growth. The timeline for this growth opportunity is dependent on the successful completion of clinical phases, potentially yielding results within the next 3-5 years.
- Strategic Partnerships: Forming strategic partnerships with larger pharmaceutical companies can provide MYND Life Sciences with access to additional funding, expertise, and distribution channels. The pharmaceutical industry is increasingly interested in novel therapies for mental health, creating opportunities for collaboration. Such partnerships could accelerate the development and commercialization of MYND's drug candidates, potentially within the next 2-3 years.
- Intellectual Property Protection: Securing strong intellectual property protection for its drug candidates and formulations is crucial for maintaining a competitive advantage. The market for patented pharmaceutical products is highly lucrative, offering significant revenue potential. MYND Life Sciences can strengthen its position by actively pursuing patents and defending its intellectual property rights, with ongoing efforts to expand its patent portfolio.
- Regulatory Approvals: Obtaining regulatory approvals from health authorities in Canada and the United States is essential for commercializing MYND's drug candidates. The regulatory approval process is rigorous and time-consuming, but successful approvals can unlock significant market opportunities. MYND Life Sciences is actively engaged in preparing its clinical trial data for submission to regulatory agencies, with potential approvals anticipated within the next 3-5 years.
- Development of Novel Analogs: MYND Life Sciences can focus on the development of novel analogs of psilocin and psilocybin with improved therapeutic properties and reduced side effects. The market for innovative pharmaceutical products is highly competitive, but successful innovation can lead to significant market share gains. MYND Life Sciences is investing in research and development to identify and characterize novel analogs, with potential breakthroughs anticipated within the next 2-4 years.
What Opportunities Does MYNDF Have?
- Expanding clinical trials to new indications.
- Securing additional funding through partnerships or grants.
- Developing novel drug delivery systems.
- Capitalizing on the growing market for mental health treatments.
What Are MYNDF's Competitive Advantages?
- Intellectual property protection through patents.
- Specialized expertise in neuro-anti-inflammatory substances.
- Established research and clinical trial infrastructure.
- Strategic partnerships with key stakeholders.
What Does MYNDF Do?
MYND Life Sciences Inc. is a life sciences company dedicated to the research and development of neuro-pharmaceutical drugs, specifically targeting depressive disorders. The company operates in Canada and the United States, focusing on advancing medicines through scientific research and clinical trials. MYND Life Sciences specializes in the analysis of psilocin and psilocybin extracts and analogs, exploring their potential therapeutic applications. The company's core mission is to develop innovative treatments for mental health conditions by leveraging neuro-anti-inflammatory substances. MYND Life Sciences is committed to rigorous scientific investigation and clinical validation to bring novel therapies to market. Headquartered in Kelowna, Canada, the company is strategically positioned to capitalize on the growing interest and investment in psychedelic-based medicines for mental health. MYND Life Sciences aims to address the unmet needs in the treatment of depressive disorders by developing pharmaceuticals that offer improved efficacy and reduced side effects compared to existing treatments. The company's focus on neuro-anti-inflammatory substances represents a novel approach to mental health treatment, potentially offering new hope for patients suffering from these conditions.
What Products and Services Does MYNDF Offer?
- Develop neuro-pharmaceutical drugs for depressive disorders.
- Conduct scientific research and clinical trials in Canada and the United States.
- Focus on medicines based on neuro-anti-inflammatory substances.
- Analyze psilocin and psilocybin extracts and analogs.
- Seek regulatory approvals for their drug candidates.
- Explore strategic partnerships with pharmaceutical companies.
- Develop novel analogs of psilocin and psilocybin.
How Does MYNDF Make Money?
- Research and development of neuro-pharmaceutical drugs.
- Conducting clinical trials to demonstrate safety and efficacy.
- Seeking regulatory approvals for commercialization.
- Potential revenue generation through drug sales and licensing agreements.
What Industry Does MYNDF Operate In?
MYND Life Sciences Inc. operates within the biotechnology industry, specifically targeting the emerging market for psychedelic-assisted therapies. The industry is experiencing increased interest and investment due to the potential of these substances to treat mental health disorders such as depression and anxiety. This market is characterized by intense competition and evolving regulatory landscapes. MYND Life Sciences aims to differentiate itself through rigorous scientific research and clinical trials, positioning itself to capitalize on the growing demand for innovative mental health treatments.
Who Are MYNDF's Key Customers?
- Patients suffering from depressive disorders.
- Healthcare providers prescribing mental health treatments.
- Pharmaceutical companies seeking to expand their product portfolios.
Company Profile
MYND Life Sciences Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Port Coquitlam, CA. The company is led by CEO Wilfred A. Jefferies. MYNDF has traded publicly since 2021.
MYNDF Revenue & Earnings Trend
In Q3 2024, MYNDF generated $0 in top-line revenue. The company recorded a net loss of $379K, with diluted EPS of $-0.01. Quarter-over-quarter revenue has been mixed, typical for a unknown company operating in Healthcare.
Key Financial Metrics
Return on equity for MYND Life Sciences Inc. stands at 35.7%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -5.9%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -45.9%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
MYND Life Sciences Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -36.44 places it in the distress zone, a signal of elevated financial risk.
MYNDF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on innovative neuro-pharmaceutical drugs.
- Expertise in psilocin and psilocybin analogs.
- Established research and clinical trial infrastructure.
- Strategic partnerships with key stakeholders.
Bear Case
- Limited financial resources.
- Reliance on successful clinical trial outcomes.
- Dependence on regulatory approvals.
- Limited commercialization experience.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $0 | -$379,274 | -$0.01 |
| Q2 2024 | $0 | -$259,564 | -$0.01 |
| Q1 2024 | $0 | -$372,764 | -$0.01 |
Based on FMP financials and quantitative analysis
MYNDF Latest News
No recent news available for MYNDF.
MYNDF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for MYNDF.
Price Targets
Wall Street price target analysis for MYNDF.
MYNDF MoonshotScore
What does this score mean?
The MoonshotScore rates MYNDF 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Wilfred A. Jefferies
CEO
Wilfred A. Jefferies is the CEO of MYND Life Sciences Inc. His background includes extensive experience in the life sciences industry, with a focus on pharmaceutical development and commercialization. He has held leadership positions in various biotechnology companies, overseeing research and development, clinical trials, and regulatory affairs. Jefferies has a proven track record of driving innovation and building successful teams. His expertise in neuro-pharmaceuticals makes him well-suited to lead MYND Life Sciences in its mission to develop novel treatments for depressive disorders.
Track Record: Under Wilfred A. Jefferies' leadership, MYND Life Sciences Inc. has focused on advancing its pipeline of neuro-pharmaceutical drug candidates through preclinical and clinical development. He has overseen the expansion of the company's research and development efforts, focusing on the analysis of psilocin and psilocybin extracts and analogs. Jefferies has also been instrumental in securing strategic partnerships and funding to support the company's growth initiatives.
MYNDF OTC Market Information
The OTC Other tier represents the lowest tier of the OTC market, indicating that MYND Life Sciences Inc. may not meet the minimum financial or disclosure requirements of higher tiers like OTCQX or OTCQB. Companies in this tier often have limited trading volume and may be subject to less stringent regulatory oversight compared to companies listed on major exchanges like the NYSE or NASDAQ. Investing in companies on the OTC Other tier carries a higher degree of risk due to the potential for limited liquidity and transparency.
- OTC Tier: OTC Other
- Limited liquidity due to low trading volume.
- Lack of transparency due to less stringent disclosure requirements.
- Potential for price volatility.
- Higher risk of fraud or manipulation.
- Limited access to company information.
- Verify the company's financial statements and disclosures.
- Research the company's management team and their track record.
- Assess the company's business model and competitive landscape.
- Evaluate the company's intellectual property and patent portfolio.
- Review the company's regulatory filings and compliance history.
- Monitor trading volume and price activity.
- Consult with a financial advisor before investing.
- Company is actively engaged in research and development.
- Company has secured patents for its drug candidates.
- Company has established partnerships with reputable organizations.
- Company has a clear business plan and strategy.
- Company is transparent about its operations and financials (to the extent available).
MYNDF Healthcare Stock FAQ
What does MYND Life Sciences Inc. do?
MYND Life Sciences Inc. is a biotechnology company focused on developing neuro-pharmaceutical drugs for the treatment of depressive disorders. The company conducts research and clinical trials in Canada and the United States, specializing in the analysis of psilocin and psilocybin extracts and analogs.
What do analysts say about MYNDF stock?
As of 2026-03-18, there is no readily available analyst consensus on MYNDF stock due to its OTC listing and limited coverage. The company's valuation is largely dependent on the successful development and commercialization of its drug candidates. Investors should conduct their own thorough research and consider the inherent risks associated with investing in early-stage biotechnology companies. Key metrics to monitor include clinical trial results, regulatory milestones, and financial performance.
What are the main risks for MYNDF?
The main risks for MYNDF include regulatory hurdles, competition from established pharmaceutical companies, and uncertainty surrounding clinical trial outcomes. As a biotechnology company focused on novel therapies, MYND Life Sciences faces the risk of failing to obtain regulatory approvals for its drug candidates. Additionally, the company operates in a highly competitive industry and must compete with larger, more established companies.
What are the key factors to evaluate for MYNDF?
Evaluate MYNDF on fundamentals, analyst consensus, and risk factors. MYND Life Sciences Inc. presents a speculative investment opportunity within the burgeoning field of psychedelic-based therapeutics. Not financial advice.
How frequently does MYNDF data refresh on this page?
MYNDF's price was last updated on Aug 20, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven MYNDF's recent stock price performance?
MYND Life Sciences Inc. (MYNDF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on innovative neuro-pharmaceutical drugs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider MYNDF overvalued or undervalued right now?
MYND Life Sciences Inc. (MYNDF) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research MYNDF before investing?
Before investing in MYND Life Sciences Inc. (MYNDF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- OTC market data may be limited and less reliable than data from major exchanges.